论文部分内容阅读
Cetus 公司宣布开始进行人肿瘤坏死因子(TNF)的临床试验,肿瘤坏死因子是从人免疫系统提取的一种蛋白质,在治疗某些癌症方面可能证明是有用的。肿病坏死因子是 Cetu公司开始对人进行试验的第三种治疗蛋白质。其它两种蛋白质是前白细胞素(R)(人重组体白细胞间素-2)和 BETASERON(R)(人重组体β干扰素)。Cetus 公司生产的肿瘤坏死因子是应用先进的基因工程技术生产的肿瘤坏死因子的类似
Cetus Corporation announced the start of a clinical trial of human tumor necrosis factor (TNF), a protein extracted from the human immune system that may prove useful in the treatment of certain cancers. Sick necrosis factor is the third therapeutic protein Cetu company began to test humans. The other two proteins are pre-leukocyte (R) (human recombinant interleukin-2) and BETASERON (R) (human recombinant beta interferon). Tumor necrosis factor produced by Cetus is similar to the tumor necrosis factor produced using advanced genetic engineering techniques